Transient inhibition of FoxP3 expression in the accumulated peripheral CD4+FoxP3+ Treg cells in aged individuals is one option, which was used in AD and displayed improvement of amyloid‐beta plaque clearance, amelioration of neuroinflammation, and recovery of cognitive decline demonstrated in an AD mouse model (Baruch et al., 2015). This evidence concerns the gene FOXP3 and Alzheimer disease.